Logo image of CORT

CORCEPT THERAPEUTICS INC (CORT) Stock Fundamental Analysis

NASDAQ:CORT - Nasdaq - US2183521028 - Common Stock - Currency: USD

73.34  -0.25 (-0.34%)

Fundamental Rating

7

Taking everything into account, CORT scores 7 out of 10 in our fundamental rating. CORT was compared to 193 industry peers in the Pharmaceuticals industry. CORT has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. CORT is not priced too expensively while it is growing strongly. Keep and eye on this one! These ratings could make CORT a good candidate for growth and quality investing.


Dividend Valuation Growth Profitability Health

Quickly go to:

8

1. Profitability

1.1 Basic Checks

CORT had positive earnings in the past year.
CORT had a positive operating cash flow in the past year.
Each year in the past 5 years CORT has been profitable.
Each year in the past 5 years CORT had a positive operating cash flow.
CORT Yearly Net Income VS EBIT VS OCF VS FCFCORT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M

1.2 Ratios

CORT's Return On Assets of 16.67% is amongst the best of the industry. CORT outperforms 97.41% of its industry peers.
The Return On Equity of CORT (21.02%) is better than 93.26% of its industry peers.
CORT has a better Return On Invested Capital (13.39%) than 90.67% of its industry peers.
CORT had an Average Return On Invested Capital over the past 3 years of 17.94%. This is above the industry average of 14.76%.
The 3 year average ROIC (17.94%) for CORT is well above the current ROIC(13.39%). The reason for the recent decline needs to be investigated.
Industry RankSector Rank
ROA 16.67%
ROE 21.02%
ROIC 13.39%
ROA(3y)17.09%
ROA(5y)19.27%
ROE(3y)20.64%
ROE(5y)22.43%
ROIC(3y)17.94%
ROIC(5y)20.7%
CORT Yearly ROA, ROE, ROICCORT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 60

1.3 Margins

With an excellent Profit Margin value of 18.66%, CORT belongs to the best of the industry, outperforming 92.23% of the companies in the same industry.
In the last couple of years the Profit Margin of CORT has declined.
CORT has a better Operating Margin (14.24%) than 84.46% of its industry peers.
In the last couple of years the Operating Margin of CORT has declined.
CORT has a better Gross Margin (98.37%) than 98.45% of its industry peers.
CORT's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 14.24%
PM (TTM) 18.66%
GM 98.37%
OM growth 3Y-15.83%
OM growth 5Y-11.04%
PM growth 3Y-12.04%
PM growth 5Y-7.41%
GM growth 3Y-0.06%
GM growth 5Y0.04%
CORT Yearly Profit, Operating, Gross MarginsCORT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40 60 80

More info and screens

8

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so CORT is still creating some value.
Compared to 1 year ago, CORT has more shares outstanding
Compared to 5 years ago, CORT has less shares outstanding
There is no outstanding debt for CORT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CORT Yearly Shares OutstandingCORT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
CORT Yearly Total Debt VS Total AssetsCORT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

CORT has an Altman-Z score of 31.02. This indicates that CORT is financially healthy and has little risk of bankruptcy at the moment.
CORT has a Altman-Z score of 31.02. This is amongst the best in the industry. CORT outperforms 95.34% of its industry peers.
CORT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 31.02
ROIC/WACC1.34
WACC10%
CORT Yearly LT Debt VS Equity VS FCFCORT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.3 Liquidity

A Current Ratio of 3.06 indicates that CORT has no problem at all paying its short term obligations.
CORT has a Current ratio of 3.06. This is comparable to the rest of the industry: CORT outperforms 54.92% of its industry peers.
CORT has a Quick Ratio of 2.98. This indicates that CORT is financially healthy and has no problem in meeting its short term obligations.
CORT has a Quick ratio (2.98) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 3.06
Quick Ratio 2.98
CORT Yearly Current Assets VS Current LiabilitesCORT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

8

3. Growth

3.1 Past

CORT shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by 0.00%.
Measured over the past years, CORT shows a quite strong growth in Earnings Per Share. The EPS has been growing by 9.71% on average per year.
Looking at the last year, CORT shows a very strong growth in Revenue. The Revenue has grown by 25.71%.
Measured over the past years, CORT shows a quite strong growth in Revenue. The Revenue has been growing by 17.11% on average per year.
EPS 1Y (TTM)0%
EPS 3Y11.69%
EPS 5Y9.71%
EPS Q2Q%-9.38%
Revenue 1Y (TTM)25.71%
Revenue growth 3Y22.64%
Revenue growth 5Y17.11%
Sales Q2Q%18.7%

3.2 Future

Based on estimates for the next years, CORT will show a very strong growth in Earnings Per Share. The EPS will grow by 56.00% on average per year.
CORT is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 30.41% yearly.
EPS Next Y13.31%
EPS Next 2Y47.92%
EPS Next 3Y70.13%
EPS Next 5Y56%
Revenue Next Year29.79%
Revenue Next 2Y32.48%
Revenue Next 3Y32.46%
Revenue Next 5Y30.41%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CORT Yearly Revenue VS EstimatesCORT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 1B 2B 3B
CORT Yearly EPS VS EstimatesCORT Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 5 10 15

More info and screens

5

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 64.90, CORT can be considered very expensive at the moment.
Based on the Price/Earnings ratio, CORT is valued a bit cheaper than the industry average as 77.20% of the companies are valued more expensively.
The average S&P500 Price/Earnings ratio is at 26.73. CORT is valued rather expensively when compared to this.
CORT is valuated quite expensively with a Price/Forward Earnings ratio of 27.03.
69.95% of the companies in the same industry are more expensive than CORT, based on the Price/Forward Earnings ratio.
Compared to an average S&P500 Price/Forward Earnings ratio of 34.61, CORT is valued a bit cheaper.
Industry RankSector Rank
PE 64.9
Fwd PE 27.03
CORT Price Earnings VS Forward Price EarningsCORT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, CORT is valued a bit cheaper than the industry average as 75.65% of the companies are valued more expensively.
Based on the Price/Free Cash Flow ratio, CORT is valued a bit cheaper than the industry average as 78.24% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 43.14
EV/EBITDA 69.5
CORT Per share dataCORT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
CORT has an outstanding profitability rating, which may justify a higher PE ratio.
CORT's earnings are expected to grow with 70.13% in the coming years. This may justify a more expensive valuation.
PEG (NY)4.88
PEG (5Y)6.68
EPS Next 2Y47.92%
EPS Next 3Y70.13%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CORT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CORCEPT THERAPEUTICS INC

NASDAQ:CORT (8/13/2025, 11:47:17 AM)

73.34

-0.25 (-0.34%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)07-31 2025-07-31/amc
Earnings (Next)10-28 2025-10-28/amc
Inst Owners80.63%
Inst Owner Change-0.02%
Ins Owners6.55%
Ins Owner Change0.39%
Market Cap7.78B
Analysts82
Price Target137.19 (87.06%)
Short Float %11.97%
Short Ratio8.46
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)34.3%
Min EPS beat(2)16.96%
Max EPS beat(2)51.63%
EPS beat(4)3
Avg EPS beat(4)17.73%
Min EPS beat(4)-40.2%
Max EPS beat(4)51.63%
EPS beat(8)7
Avg EPS beat(8)18.86%
EPS beat(12)9
Avg EPS beat(12)14.75%
EPS beat(16)12
Avg EPS beat(16)12.32%
Revenue beat(2)0
Avg Revenue beat(2)-8.89%
Min Revenue beat(2)-13.38%
Max Revenue beat(2)-4.4%
Revenue beat(4)1
Avg Revenue beat(4)-5.99%
Min Revenue beat(4)-13.38%
Max Revenue beat(4)4.07%
Revenue beat(8)5
Avg Revenue beat(8)-1.83%
Revenue beat(12)6
Avg Revenue beat(12)-1.82%
Revenue beat(16)7
Avg Revenue beat(16)-2.2%
PT rev (1m)-2.71%
PT rev (3m)-3.58%
EPS NQ rev (1m)-17.28%
EPS NQ rev (3m)-34.31%
EPS NY rev (1m)0%
EPS NY rev (3m)-18.73%
Revenue NQ rev (1m)-9.6%
Revenue NQ rev (3m)6.53%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.7%
Valuation
Industry RankSector Rank
PE 64.9
Fwd PE 27.03
P/S 10.86
P/FCF 43.14
P/OCF 42.68
P/B 12.23
P/tB 12.23
EV/EBITDA 69.5
EPS(TTM)1.13
EY1.54%
EPS(NY)2.71
Fwd EY3.7%
FCF(TTM)1.7
FCFY2.32%
OCF(TTM)1.72
OCFY2.34%
SpS6.75
BVpS6
TBVpS6
PEG (NY)4.88
PEG (5Y)6.68
Profitability
Industry RankSector Rank
ROA 16.67%
ROE 21.02%
ROCE 15.52%
ROIC 13.39%
ROICexc 28.18%
ROICexgc 28.18%
OM 14.24%
PM (TTM) 18.66%
GM 98.37%
FCFM 25.18%
ROA(3y)17.09%
ROA(5y)19.27%
ROE(3y)20.64%
ROE(5y)22.43%
ROIC(3y)17.94%
ROIC(5y)20.7%
ROICexc(3y)74.13%
ROICexc(5y)85.06%
ROICexgc(3y)74.13%
ROICexgc(5y)85.06%
ROCE(3y)20.79%
ROCE(5y)23.98%
ROICexcg growth 3Y-18.86%
ROICexcg growth 5Y-17.58%
ROICexc growth 3Y-18.86%
ROICexc growth 5Y-17.58%
OM growth 3Y-15.83%
OM growth 5Y-11.04%
PM growth 3Y-12.04%
PM growth 5Y-7.41%
GM growth 3Y-0.06%
GM growth 5Y0.04%
F-Score6
Asset Turnover0.89
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 101.43%
Cap/Sales 0.27%
Interest Coverage 250
Cash Conversion 175.46%
Profit Quality 134.88%
Current Ratio 3.06
Quick Ratio 2.98
Altman-Z 31.02
F-Score6
WACC10%
ROIC/WACC1.34
Cap/Depr(3y)72.82%
Cap/Depr(5y)100.78%
Cap/Sales(3y)0.15%
Cap/Sales(5y)0.19%
Profit Quality(3y)125.51%
Profit Quality(5y)133.52%
High Growth Momentum
Growth
EPS 1Y (TTM)0%
EPS 3Y11.69%
EPS 5Y9.71%
EPS Q2Q%-9.38%
EPS Next Y13.31%
EPS Next 2Y47.92%
EPS Next 3Y70.13%
EPS Next 5Y56%
Revenue 1Y (TTM)25.71%
Revenue growth 3Y22.64%
Revenue growth 5Y17.11%
Sales Q2Q%18.7%
Revenue Next Year29.79%
Revenue Next 2Y32.48%
Revenue Next 3Y32.46%
Revenue Next 5Y30.41%
EBIT growth 1Y-20.33%
EBIT growth 3Y3.23%
EBIT growth 5Y4.18%
EBIT Next Year-34.64%
EBIT Next 3Y41.42%
EBIT Next 5Y19.15%
FCF growth 1Y33.84%
FCF growth 3Y5.38%
FCF growth 5Y7.73%
OCF growth 1Y34.76%
OCF growth 3Y5.66%
OCF growth 5Y7.79%